In vivo genotoxicity testing strategies: Report from the 7th International Workshop on Genotoxicity Testing (IWGT)

Publication date: Available online 25 April 2019Source: Mutation Research/Genetic Toxicology and Environmental MutagenesisAuthor(s): David Kirkland, Yoshifumi Uno, Mirjam Luijten, Carol Beevers, Jan van Benthem, Brian Burlinson, Stephen Dertinger, George R. Douglas, Shuichi Hamada, Katsuyoshi Horibata, David P. Lovell, Mugimane Manjanatha, Hans-Joerg Martus, Nan Mei, Takeshi Morita, Wakako Ohyama, Andrew WilliamsAbstractThe working group reached complete or majority agreement on many issues.Results from TGR and in vivo comet assays for 91 chemicals showed they have similar ability to detect in vivo genotoxicity per se with bacterial mutagens and Ames-positive carcinogens.TGR and comet assay results were not significantly different when compared with IARC Group 1, 2 A, and unclassified carcinogens. There were significantly more comet assay positive responses for Group 2B chemicals, and for IARC classified and unclassified carcinogens combined, which may be expected since mutation is a sub-set of genotoxicity.A liver comet assay combined with the bone marrow/blood micronucleus (MNviv) test would detect in vivo genotoxins that do not exhibit tissue-specific or site-of-contact effects, and is appropriate for routine in vivo genotoxicity testing.Generally for orally administered substances, a comet assay at only one site-of-contact GI tract tissue (stomach or duodenum/jejunum) is required.In MNviv tests, evidence of target tissue exposure can be obtained in a number of different...
Source: Mutation Research Genetic Toxicology and Environmental Mutagenesis - Category: Genetics & Stem Cells Source Type: research